Introduction

The concurrent infection of influenza and pneumococcus is commonly observed during the circulation of influenza, and both infection causes the leading mortality in the elderly [1,2]. Vaccination against both of these diseases is important to prevent infections and their complications [3-6]. Delivering both vaccines together not only increases the vaccination rate but also decreases mortality and hospitalization rates in the elderly [7-9]. However, only 20%-40% of older adults receive pneumococcal vaccine in...
most countries [10]. In the Republic of Korea, concomitant administration of the influenza vaccine and the pneumococcal vaccine has been recommended to improve the vaccination rates during the influenza vaccination period [11].

At the time of this study, a 13-valent pneumococcal conjugate vaccine (PCV13) and a 23-valent polysaccharide pneumococcal vaccine (PPV23) were introduced for adults in Korea. However, there was no preferential recommendation for use of PCV13 or PPV23 targeting the elderly. The selection of pneumococcal vaccine type was totally depended on vaccinators' opinion.

Comparability of immunogenicity and safety of trivalent inactivated influenza vaccine (IIV3) co-administered with PPV23 or PCV13 has been previously demonstrated [12,13]. However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or IIV3 given with PPV23 in the elderly. We performed a multicenter, randomized, comparative study in people aged 65 years or older who had not previously received a pneumococcal vaccine. This study will clarify the relative immunogenicity and tolerability of IIV3 when simultaneously administered with PCV13 or PPV23.

Material and Methods

Study participants
The multicenter, randomized, comparative study was conducted during the 2012-2013 influenza vaccination period. (Clinical Trial Number: NCT0258047) Participants were enrolled at two centers during the last week of October 2012. Eligible participants were healthy men and women aged 65 years or older who were naïve to the 2012/2013 season influenza vaccine and any pneumococcal vaccine. Exclusion criteria were as follows: known egg allergy, febrile illness on the day of vaccination, any other vaccination within the previous 30 days, immunodeficiency or suppression, treatment with immunoglobulins during the past 3 months, a history of Strep-tococcal pneumoniae infection within the previous 5 years, and any conditions which might interfere with the study results.

Vaccines and administration
PCV13 (Prevenar 13, Wyeth Pharmaceuticals Inc., Marietta, GA, USA) contained polysaccharides of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F conjugated to a nontoxic mutant form of diphtheria toxin cross-reactive material 197. Each 0.5-mL vial contained 2.2 μg of each serotype, except type 6B, which was included at 4.4 μg.

PPV23 (Pneumovax 23, Merck & Company, Inc., Kenilworth, NJ, USA) consisted of a purified capsular polysaccharide from 12 of the serotypes included in PCV13 (all except 6A), as well as 11 additional serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F). The vaccine was formulated to contain 25 μg of each of the 23 purified polysaccharide serotypes per 0.5 mL vial.

IIV3 (GCflu, Green Cross Corp., Yongin, Korea) was formulated according to the World Health Organization recommendations for the 2012/2013 (northern hemisphere) flu season and contained 15 μg hemagglutinin for each of the three influenza strains per 0.5 mL vial: an A/California/7/2009 (H1N1)-like virus, an A/Victoria/361/2011 (H3N2)-like virus, and a B/Hubei-Wujiaang/158/2009-like virus.

All eligible participants randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio using an excel-based randomization program. The influenza vaccine was administered to the right deltoid and the pneumococcal vaccines were administered to the left deltoid.

Immunogenicity assessments
We obtained blood samples from each patient before vaccination and then at 28±7 days after vaccination. Hemagglutination-inhibiting (HI) antibodies were measured by a standard microtiter assay using washed turkey erythrocytes [14,15]. The serum HI antibodies were determined in the range of 1:10 to 1:5,120. A titer of <1:10 was assigned a value of 1:5, while titers above 1:5,120 were assigned a value of 1:5,120.

Geometric mean titer (GMT), seroprotection rate (proportion of subjects with a post-vaccination titer ≥1:40), seroconversion rate (proportion of subjects with ≥fourfold increase in titer from pre-vaccination titer or a post-vaccination ≥1:40 if the pre-vaccination titer was <1:40), and GMT fold (GMT ratio of the post-vaccination titer to pre-vaccination titer) were measured. The criteria of the Committee for Medical Products for Human Use (CHMP) was applied to evaluate immunogenicity; seroprotection rate >60%, seroconversion rate >30%, and GMT fold >2.

Safety assessments
Any solicited local or systemic reactions to both vaccines were monitored using a clinical diary for seven days after vaccination. Participants were asked to record pain, tenderness, and redness diameter at both injection sites and the severity of systemic symptoms such as headache, malaise, chills, muscle
aches, arthralgia, and any other adverse events, according to the Food and Drug Administration Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials [16].

Statistical analysis
To estimate local and systemic reactions, the proportions of subjects experiencing reactions were calculated based on the frequency and severity from their submitted diary. The 95% confidence interval was calculated using the Student’s t-distribution, assuming a normal distribution of the log$_{10}$ titer. Two-tailed Fisher exact tests were used to compare both groups. All reported p-values are two-sided, and values of 0.05 or less are considered statistically significant. Data analysis was performed using SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA).

Results
Study subjects
A total of 224 participants were enrolled in the study (PCV13+IIV3, n = 112; PPV23+IIV3, n = 112). Of the 224 subjects, 4 participants withdrew consents after vaccination due to personal reasons. Finally, blood samples for analysis of immunogenicity and clinical diaries for safety analysis were available from 220 participants (PCV13+IIV3, n = 110; PPV23+IIV3, n = 110).

No gender difference was seen between two groups (male 46.2% vs. 45.5%, p = 0.413). The median ages of subjects were 72 and 73 years, respectively, and were not also statistically different.

Immunogenicity response to IIV3
The immunogenicity data for all three influenza virus strains are summarized in Table 1 and Fig. 1. Pre-vaccination GMTs for each strain were similar between the two groups (A/H1N1, p = 0.603; A/H3N2, p = 0.737; B, p = 0.555). One month after vaccination, the GMTs had increased significantly in both vaccine groups for all three strains. The changes in GMTs for A/H3N2 and B were not different. However, the GMTs for A/H1N1 were significantly higher in PCV13+IIV3 than in PPV23+IIV3 (p = 0.026). Both groups satisfied all three CHMP criteria for A/H1N1 and A/H3N2 strains, showing comparable seroprotection and seroconversion rates. As for the influenza B strain, neither group showed a sufficient seroconversion rate or increase in GMT. However, both groups satisfied the seroprotection rate criteria. Overall, the assessments of all three criteria were similar in both groups (seroprotection rate, p > 0.990; seroconversion rate, p = 0.746; GMT fold, p = 0.588).

Safety
The overall incidence of local reaction is shown in Tables 2

Table 1. Antibody responses as measured with the hemagglutination-inhibition assay according to vaccine group

|                | A/H1N1                      | A/H3N2                      | B                      |
|----------------|-----------------------------|-----------------------------|------------------------|
|                | PPV23 (n = 110)             | PCV13 (n = 110)             | PPV23 (n = 110)        | PCV13 (n = 110) | PPV23 (n = 110) | PCV13 (n = 110) | p-value |
| GMT (95% CI)   |                             |                             |                         |                  |
| At pre-vaccination | 22.3 (17.5-27.9)            | 24.3 (19.4-30.3)            | 54.1 (43.1-68.3)       | 57.3 (45.1-72.8) | 0.603           |                  |
| At post 1 mo$^a$ | 66.4 (55.1-80.1)            | 89.9 (74.5-108.4)           | 149.5 (125.5-178.1)    | 158.7 (133.2-189.1) | 0.026           |                  |
| Seroprotection rate (95% CI, %) |                             |                             |                         |                  |
| At pre-vaccination | 36.3 (27.4-45.1)            | 38.9 (30.1-47.8)            | 67.3 (58.4-76.1)       | 69.9 (61.1-77.9) | 0.784           |                  |
| At post 1 mo     | 76.4 (67.3-84.5)            | 83.6 (77.3-90.0)            | 93.6 (88.2-98.2)       | 93.6 (88.2-98.2) | 0.238           |                  |
| Seroconversion rate (95% CI, %)      |                             |                             |                         |                  |
| At post 1 mo     | 35.5 (26.4-44.5)            | 48.2 (38.2-58.2)            | 38.2 (29.1-48.2)       | 41.8 (31.8-51.8) | 0.075           |                  |
| GMT fold (95% CI) |                             |                             |                         |                  |
| At post 1 mo     | 2.9 (2.3-3.6)               | 3.8 (3.0-4.7)               | 2.7 (2.2-3.4)          | 2.8 (2.3-3.5)   | 0.104           |                  |

PPV23, 23-valent polysaccharide pneumococcal vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; GMT, geometric mean titer; CI, confidence interval.

$^a$Post-vaccination GMT was adjusted according to pre-vaccination titer.
Fig. 1. Changes of geometric mean titer (GMT), seroprotection rate, seroconversion rate, and GMT fold after vaccination. Serum samples collected from elderly volunteers vaccinated with trivalent inactivated influenza vaccine (IIV3) simultaneously with either 13-valent pneumococcal conjugate vaccine (PCV13) or 23-valent polysaccharide pneumococcal vaccine (PPV23) before vaccination and 1 month after vaccination were tested by hemagglutination inhibition assay. The GMT (A), the seroprotection rate (proportion of subjects with a post-vaccination titer ≥ 1:40) (B), seroconversion rate (proportion of subjects with ≥ 4-fold increase in titer from pre-vaccination titer or a post-vaccination ≥ 1:40 if the pre-vaccination titer was < 1:40) (C), and GMT fold (GMT ratio of the post-vaccination titer to pre-vaccination titer) (D) were measured. The dotted lines indicate the criteria of the Committee for Medical Products for Human Use (CHMP). *Significantly different between two groups.

Table 2. Local adverse effects within 7 days

| Local reaction | Pneumococcal vaccination site (n = 220) | Influenza vaccination site (n = 220) | p-value | p-value |
|----------------|-----------------------------------------|-------------------------------------|---------|---------|
|                | PPV23 (n = 110)                          | PCV13 (n = 110)                    |         |         |
| Pain           |                                          |                                    | 0.888   | 0.372   |
| None           | 85 (77.3)                                | 82 (74.5)                          |         |         |
| Mild           | 23 (20.9)                                | 26 (23.6)                          |         |         |
| Moderate       | 2 (1.8)                                  | 2 (1.8)                            |         |         |
| Severe         | 0 (0)                                    | 0 (0)                              |         |         |
| Tenderness     |                                          |                                    | 0.827   | >0.990  |
| None           | 89 (80.9)                                | 87 (79.1)                          |         |         |
| Mild           | 20 (18.2)                                | 21 (19.1)                          |         |         |
| Moderate       | 1 (0.9)                                  | 2 (1.8)                            |         |         |
| Severe         | 0 (0)                                    | 0 (0)                              |         |         |
| Redness diameter (mm) |                                    |                                    | 0.613   | >0.990  |
| 0              | 109 (96.5)                               | 105 (94.6)                         |         |         |
| 1-4            | 10 (9.1)                                 | 8 (7.3)                            |         |         |
| ≥ 5            | 1 (0.9)                                  | 0 (0)                              |         |         |
| Swelling diameter (mm) |                                    |                                    | 0.192   | 0.368   |
| 0              | 109 (96.5)                               | 108 (97.3)                         |         |         |
| 1-4            | 6 (5.5)                                  | 2 (1.8)                            |         |         |
| ≥ 5            | 0 (0)                                    | 0 (0)                              |         |         |

Values are presented as number (%). PPV23, 23-valent polysaccharide pneumococcal vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
Concomitant administration of influenza and pneumococcal vaccines has been evaluated from various perspectives. Previous studies have mentioned that the influenza vaccine could be administered simultaneously with pneumococcal vaccine without affecting immunogenicity and safety. A prospective study of 152 adult participants with chronic respiratory disease suggested that concomitant immunization with PPV23 and influenza vaccine was well tolerated and immunogenically effective at one month after vaccination [17]. Other studies also demonstrated that concomitant PCV13 administration with the influenza vaccine yielded acceptable immunogenicity and safety in the elderly [13,18]. However, there is no study that directly compared the immunogenicity and safety of influenza vaccine given concomitantly with either PCV13 or PPV23 in the elderly.

This study demonstrated that both IIV3+PCV13 and IIV3+PPV23 showed excellent immunogenicity. It is noted that the post-vaccination GMTs of IIV3+PCV13 for A/H1N1 were significantly higher compared with IIV3+PPV23. Although not statistically significant, IIV3+PCV13 showed a relatively higher seroprotection rate, seroconversion rate, and GMT fold for A/H1N1. The higher immune response observed by IIV+PCV13 is not well understood. Such additive effects could be caused by multifactorial immune interaction. Possible explanation for such phenomenon would be that more immunogenic stimuli of PCV leads to promote the MHC class I and II antigen processing and presentation pathways, which also produce more immunogenic response to influenza vaccine. However, such effect is initiated by local environment and two vaccines were separately administered in each arm, so the assumption could be easily broken. In addition, those could be incidental findings due to the small number of participants in the study group. Further large-scale studies are needed to confirm this finding.

Local and systemic reactions did not differ significantly between IIV3+PCV13 and IIV3+PPV23. Overall, there were no vaccine-related serious adverse events and solicited reactions were mild. Importantly, our study indicates that concomitant vaccination for influenza and pneumococcal disease was safe and generally well tolerated in elderly participants.

This study has several limitations. First, influenza vaccination history and infection status in previous years were not available. Pre-vaccination GMTs were already high in some participants, and could influence immunogenicity. Second, as noted above, this study was performed in a small sample of elderly participants. Further studies, with larger sample sizes, are needed to confirm our findings.
in the present study, a solitary IIV3 administration group was not included. Simultaneous vaccination could influence the immunogenicity of each vaccine. In such situations, having a solitary IIV3 group might be needed to explain the differences of immunogenicity. Third, immunogenicity of pneumococcal vaccine was not assessed. One study which compared PCV13+IIV3 with IIV showed slightly lower immune reaction of PCV13 in concomitant vaccination group [13]. However, other study found no differences [19]. Inconclusive result needs to be confirmed by addition studies. Current study found similar immunogenicity and safety profiles in response to IIV3 when PCV13 or PPV23 were administered together.

ORCID

Yu Bin Seo http://orcid.org/0000-0001-5183-1996
Won Suk Choi http://orcid.org/0000-0001-5874-4764
Jacob Lee http://orcid.org/0000-0002-3160-1314
Joon Young Song http://orcid.org/0000-0002-0148-7194
Hee Jin Cheong http://orcid.org/0000-0002-2532-1463
Woo Joo Kim http://orcid.org/0000-0002-4546-3880

References

1. Walter ND, Taylor TH, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010;50:175-83.
2. Grabowska K, Hogberg L, Penttinen P, Svensson A, Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis 2006;6:58.
3. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004;190:1-10.
4. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-81.
5. Mooney JD, Weir A, McMenamin J, et al. Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J 2013;54:469-75.
6. Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996;156:205-8.
7. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999;17 Suppl 1:S91-3.
8. Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. Vaccine 2011;29:5195-202.
9. Hannoun C, Mega F, Piery J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-8.
10. Song JY, Cheong HJ, Woo HJ, et al. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. J Korean Med Sci 2011;26:191-5.
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville: U.S. Department of Health and Human Services; 2007.
12. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients
with chronic respiratory disease. BMJ 1997;314:1663-5.

18. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012;19:1296-303.

19. Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 2015;33:4647-52.